Brief: Ipa’S Subsidiary Biostrand And Briacell Announce Artificial Intelligence Collaboration And License Agreement To Discover And Develop Anti-Cancer Antibodies
30/11/2022 13:09
Nov 30 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* IPA’S SUBSIDIARY BIOSTRAND AND BRIACELL ANNOUNCE
ARTIFICIAL
INTELLIGENCE COLLABORATION AND LICENSE AGREEMENT TO DISCOVER AND
DEVELOP ANTI-CANCER ANTIBODIES
Source text for Eikon: ID:nBw8hQNj4a
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mindwalk Holdings
See all newsBrief: Mindwalk Holdings Corp. Announces Leadership Update
MindWalk Holdings Corp reports results for the quarter ended July 31 - Earnings Summary
Canada's MindWalk Q1 net loss widens on higher sales, marketing expenses
MindWalk Holdings Corp expected to post a loss of 8 cents a share - Earnings Preview
Brief: MindWalk Showcases Reefiq™ For Ai Drug Discovery At AMD Advancing Ai